Payment overview · 2025
General Payments
$5,119.08
261 reported records · 42 companies
Healthcare provider profile · identity verified
Danny R. Bartel, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WICHITA FALLS, TX · NPI 1679535843
Verified facts
What the public records show
CMS Open Payments records show Danny R. Bartel, M.D. received $5,119.08 in general payments during 2025 across 261 reported records.
UCB, Inc. accounted for 9.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gamunex-C, Ingrezza, Nayzilam, Nuplazid, Nurtec Odt, Qulipta, Radicava, Tysabri, Ubrelvy, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vumerity by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Zeposia by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rituxan as an associated drug or biological on 61 records involving 21 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rituxan by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Gamunex-C by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xcopri by this doctor in 2024.
Tanabe Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Radicava as an associated drug or biological on 2137 records involving 1340 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Radicava by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $487.53 | 9.5% | 25 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $397.81 | 7.8% | 20 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $335.67 | 6.6% | 18 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $303.81 | 5.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $265.29 | 5.2% | 20 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $221.40 | 4.3% | 16 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$217.06 | 4.2% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $198.93 | 3.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.28 | 3.9% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $193.27 | 3.8% | 13 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $182.55 | 3.6% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $177.84 | 3.5% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.78 | 3.2% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $160.71 | 3.1% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $156.45 | 3.1% | 7 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $132.25 | 2.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $131.29 | 2.6% | 6 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $124.30 | 2.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $112.84 | 2.2% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $107.17 | 2.1% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $92.93 | 1.8% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $90.50 | 1.8% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.70 | 1.8% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $77.82 | 1.5% | 5 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $73.92 | 1.4% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $50.40 | 1.0% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $45.54 | 0.9% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.44 | 0.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.22 | 0.7% | 2 | 2025 |
| NEUROPACE, INC. | Unresolved — no canonical attribution shown | $33.00 | 0.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $26.45 | 0.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.03 | 0.4% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $21.89 | 0.4% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $21.48 | 0.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $20.75 | 0.4% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.85 | 0.3% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.70 | 0.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.35 | 0.3% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$15.11 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.26 | 0.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $7.75 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,962.89 | 257 |
| Education | $156.19 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $335.67 | 18 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $303.81 | 4 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $286.73 | 15 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $261.11 | 13 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $240.68 | 12 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $221.40 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $199.42 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $199.42 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $198.93 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $193.27 | 13 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $182.55 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $177.84 | 9 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $160.71 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $157.36 | 15 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $156.45 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $138.87 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $131.29 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $112.84 | 7 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $111.83 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $107.17 | 6 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $92.93 | 5 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $90.50 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $89.70 | 4 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $88.34 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $87.78 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $78.00 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $77.82 | 5 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $73.92 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $73.07 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $65.87 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $65.87 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $61.95 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $50.40 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| RNS Neurostimulator Kit Normalized: rns neurostimulator kit |
Device | NEUROPACE, INC. | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $7.75 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 63 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 93 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Radicava radicava |
2025 | Radicava | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Rituxan open payments reported associated product |
CMS Open Payments — General Payments 61 supporting records · 21 recipient NPIs · example record 1211490411 |
Rituxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Tanabe Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | Radicava open payments reported associated product |
CMS Open Payments — General Payments 2137 supporting records · 1340 recipient NPIs · example record 1243917330 |
Radicava · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 935 | 214 |
| Gabapentin | Gabapentin | 676 | 140 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 506 | 121 |
| Meloxicam | Meloxicam | 488 | 127 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 410 | 62 |
| Dexamethasone | Dexamethasone | 394 | 131 |
| Clopidogrel | Clopidogrel Bisulfate | 384 | 102 |
| Oxcarbazepine | Oxcarbazepine | 380 | 72 |
| Pregabalin | Pregabalin | 299 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 295 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 234 | 55 |
| Meclizine Hcl | Meclizine Hcl | 224 | 60 |
| Topiramate | Topiramate | 217 | 54 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 191 | 65 |
| Zonisamide | Zonisamide | 188 | 41 |
| Sertraline Hcl | Sertraline Hcl | 176 | 41 |
| Allopurinol | Allopurinol | 173 | 46 |
| Propranolol Hcl | Propranolol Hcl | 173 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 46 |
| Donepezil Hcl | Donepezil Hcl | 164 | 51 |
| Trazodone Hcl | Trazodone Hcl | 164 | 40 |
| Celecoxib | Celecoxib | 157 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 150 | 50 |
| Potassium Chloride | Potassium Chloride | 149 | 36 |
| Prednisone | Prednisone | 149 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 149 | 33 |
| Lamotrigine | Lamotrigine | 148 | 28 |
| Baclofen | Baclofen | 147 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 33 |
| Nourianz | Istradefylline | 141 | 30 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 138 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 34 |
| Primidone | Primidone | 136 | 36 |
| Leflunomide | Leflunomide | 132 | 29 |
| Aptiom | Eslicarbazepine Acetate | 131 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 129 | 31 |
| Tramadol Hcl | Tramadol Hcl | 127 | 44 |
| Azathioprine | Azathioprine | 116 | 26 |
| Galantamine Er | Galantamine Hbr | 112 | 21 |
| Clonazepam | Clonazepam | 111 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 26 |
| Verapamil Hcl | Verapamil Hcl | 108 | 24 |
| Nurtec Odt | Rimegepant Sulfate | 93 | 23 |
| Imipramine Hcl | Imipramine Hcl | 91 | 19 |
| Lacosamide | Lacosamide | 90 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 89 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 87 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 83 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 82 | 17 |
| Spironolactone | Spironolactone | 78 | 27 |
| Nortriptyline Hcl | Nortriptyline Hcl | 74 | 14 |
| Tysabri | Natalizumab | 74 | suppressed |
| Alprazolam | Alprazolam | 73 | 31 |
| Methocarbamol | Methocarbamol | 73 | 15 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 68 | suppressed |
| Eliquis | Apixaban | 67 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 13 |
| Kesimpta Pen | Ofatumumab | 63 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 63 | 11 |
| Teriflunomide | Teriflunomide | 63 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 62 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 60 | 19 |
| Doxepin Hcl | Doxepin Hcl | 59 | 15 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 59 | 14 |
| Promethazine Hcl | Promethazine Hcl | 57 | 21 |
| Divalproex Sodium | Divalproex Sodium | 54 | 13 |
| Montelukast Sodium | Montelukast Sodium | 53 | 14 |
| Galantamine Hbr | Galantamine Hbr | 51 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 15 |
| Carbamazepine Er | Carbamazepine | 48 | 11 |
| Methotrexate | Methotrexate Sodium | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 16 |
| Rufinamide | Rufinamide | 45 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 11 |
| Phenytek | Phenytoin Sodium Extended | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 42 | suppressed |
| Carbamazepine | Carbamazepine | 41 | suppressed |
| Losartan Potassium | Losartan Potassium | 40 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 38 | 13 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 37 | suppressed |
| Furosemide | Furosemide | 37 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 36 | suppressed |
| Lisinopril | Lisinopril | 35 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 12 |
| Carvedilol | Carvedilol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Xcopri | Cenobamate | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 11 |
| Omeprazole | Omeprazole | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Dalfampridine Er | Dalfampridine | 27 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Vumerity | Diroximel Fumarate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Rituxan | Rituximab | 15 | suppressed |
| Aubagio | Teriflunomide | 14 | suppressed |
| Nayzilam | Midazolam | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Radicava | Edaravone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Mayzent | Siponimod | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,119.08 · 261 records | UCB, Inc. | ACTHAR, AUSTEDO XR, Azstarys, BOTOX, BRIUMVI, Briviact, CREXONT, CUTAQUIG, EPIDIOLEX, Fintepla, GOMEKLI, Gamunex-C, Hizentra, INBRIJA, INGREZZA, KESIMPTA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, Quzyttir, RNS Neurostimulator Kit, Radicava, Rystiggo, SKYCLARYS, SPINRAZA, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error